National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for <i>Pseudomonas aeruginosa</i>

National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for <i>Pseudomonas aeruginosa</i>

Background: Meropenem–vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an effective inhibitor of KPC enzymes in vitro. This s...

Full description

Saved in:
Bibliographic Details
Main Authors: Aurélien Dinh, Alexandre Bleibtreu, Clara Duran, Frédérique Bouchand, Alexie Bosch, Jullien Crozon-Clauzel, Mariam Roncato-Saberan, Morgan Matt, André Boibieux, Annlyse Fanton, Heidi Wille, Elise Fiaux, Benoît Pilmis, Marie Lacoste, Quentin Saint-Genis, Caroline Thumerelle, Patricia Pavese, Fanny Vuotto, Eric Senneville, Anaïs Potron, Stéphane Corvec, David Boutoille, Katy Jeannot, Laurent Dortet, on behalf of the Meropenem-Vaborbactam French Study Group
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Antibiotics
Subjects:
meropenem–vaborbactam
bacterial resistance
carbapenem
respiratory tract infection
<i>Pseudomonas aeruginosa</i>
Online Access:https://www.mdpi.com/2079-6382/13/12/1152
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2079-6382/13/12/1152

Similar Items